BR0204863A - Inibidores da aminotransferase dependente de aminoacidos de cadeia ramificada e a sua utilização no tratamento de doenças neurodegenerativas - Google Patents

Inibidores da aminotransferase dependente de aminoacidos de cadeia ramificada e a sua utilização no tratamento de doenças neurodegenerativas

Info

Publication number
BR0204863A
BR0204863A BR0204863-9A BR0204863A BR0204863A BR 0204863 A BR0204863 A BR 0204863A BR 0204863 A BR0204863 A BR 0204863A BR 0204863 A BR0204863 A BR 0204863A
Authority
BR
Brazil
Prior art keywords
treatment
neurodegenerative diseases
amino acid
chain amino
inhibitors
Prior art date
Application number
BR0204863-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Lain-Yen Hu
Suzanne Ross Kesten
Huangshu Lei
Todd Robert Ryder
David Juergen Wustrow
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of BR0204863A publication Critical patent/BR0204863A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/48Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom
    • C07C311/49Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom to nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BR0204863-9A 2001-11-27 2002-11-26 Inibidores da aminotransferase dependente de aminoacidos de cadeia ramificada e a sua utilização no tratamento de doenças neurodegenerativas BR0204863A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33363601P 2001-11-27 2001-11-27

Publications (1)

Publication Number Publication Date
BR0204863A true BR0204863A (pt) 2004-06-15

Family

ID=23303625

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0204863-9A BR0204863A (pt) 2001-11-27 2002-11-26 Inibidores da aminotransferase dependente de aminoacidos de cadeia ramificada e a sua utilização no tratamento de doenças neurodegenerativas

Country Status (8)

Country Link
US (2) US6809119B2 (enExample)
EP (1) EP1314723A1 (enExample)
JP (1) JP2003206273A (enExample)
AU (1) AU2002365311A1 (enExample)
BR (1) BR0204863A (enExample)
CA (1) CA2412466A1 (enExample)
MX (1) MXPA02010231A (enExample)
WO (1) WO2003045902A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI252847B (en) * 2001-07-10 2006-04-11 Synta Pharmaceuticals Corp Synthesis of taxol enhancers
MXPA02010231A (es) * 2001-11-27 2004-12-13 Warner Lambert Co Inhibidores aminotransferasa dependientes de aminoacidos de cadena ramificada y su uso en el tratamiento de las enfermedades neurodegenerativas.
WO2006113695A1 (en) * 2005-04-15 2006-10-26 Synta Pharmaceuticals Corp. Combination cancer therapy with bis(thiohydrazide) amide compounds
WO2008024303A2 (en) 2006-08-21 2008-02-28 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
EP2076254A2 (en) * 2006-08-31 2009-07-08 Synta Pharmaceuticals Corporation Combination with bis(thiohydrazide amides) for treating cancer
WO2008136976A2 (en) 2007-04-30 2008-11-13 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
TWI490214B (zh) 2008-05-30 2015-07-01 艾德克 上野股份有限公司 苯或噻吩衍生物及該等作為vap-1抑制劑之用途
WO2012033720A1 (en) 2010-09-08 2012-03-15 Wellstat Therapeutics Corporation Benzoic acid compounds for reducing uric acid
EA024194B8 (ru) * 2011-01-21 2016-11-30 Сан Фарма Адвансед Ресьорч Компани Лтд Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы
EP2481801A1 (en) 2011-01-28 2012-08-01 Deutsches Krebsforschungszentrum Inhibitors of branched-chain-aminotransferase-1 (BCAT1) for the treatment of neoplasia
WO2014049471A1 (en) * 2012-09-29 2014-04-03 Mahesh Kandula Compositions and methods for the treatment of ventricular arrhythmias and cardiovascular diseases
CN104610105B (zh) * 2015-02-13 2016-04-06 佛山市赛维斯医药科技有限公司 烷基取代的苯磺酰肼类gpr119激动剂、制备方法及其用途
CN104592066B (zh) * 2015-02-13 2016-04-06 佛山市赛维斯医药科技有限公司 一类苯磺酰肼化合物、制备方法及其用途
CN104649937B (zh) * 2015-02-13 2016-04-13 佛山市赛维斯医药科技有限公司 苯磺酰肼类gpr119激动剂、制备方法及其用途
CN104592065B (zh) * 2015-02-13 2016-04-06 佛山市赛维斯医药科技有限公司 卤代苯磺酰肼类gpr119激动剂、制备方法及其用途
CN104649944B (zh) * 2015-02-13 2016-08-31 佛山市赛维斯医药科技有限公司 一类甲氧苯磺酰肼类gpr119激动剂、制备方法及其用途
CN104649938B (zh) * 2015-02-13 2016-06-01 佛山市赛维斯医药科技有限公司 硝基苯磺酰肼类gpr119激动剂、制备方法及其用途
CN104610104B (zh) * 2015-02-13 2016-06-01 佛山市赛维斯医药科技有限公司 一种含苯磺酰肼和硝基苯结构gpr119激动剂及其用途
CN104610103B (zh) * 2015-02-13 2016-04-06 佛山市赛维斯医药科技有限公司 含苯磺酰肼和卤代苯结构gpr119激动剂、制备方法及其用途
CN104628612B (zh) * 2015-02-13 2016-06-01 佛山市赛维斯医药科技有限公司 一类腈基苯磺酰肼类gpr119激动剂、制备方法及其用途
GB201510019D0 (en) * 2015-06-09 2015-07-22 Cancer Therapeutics Crc Pty Ltd Compounds
TWI879949B (zh) * 2020-04-27 2025-04-11 南韓商奧土擇破利悟股份有限公司 用於ubr盒結構域配體之化合物、組成物以及醫藥組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2212829A1 (en) * 1995-02-21 1996-08-29 Jiro Takeo Glutamic acid receptor agonist
FR2792314B1 (fr) * 1999-04-15 2001-06-01 Adir Nouveaux composes aminotriazoles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EE200100416A (et) * 1999-12-08 2002-12-16 Warner-Lambert Company Hargneva ahelaga aminohappe-sõltuvad aminotransferaasinhibiitorid ja nende kasutamine diabeetilise retinopaatia ravis
JP2004509880A (ja) * 2000-09-19 2004-04-02 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 分枝鎖アミノ酸依存性アミノトランスフェラーゼ阻害剤及び神経退行性疾患の治療におけるそれらの使用
WO2002044126A2 (en) * 2000-11-28 2002-06-06 Guilford Pharmaceuticals Inc. Bisubstituted carbocyclic cyclophilin binding compounds and theirus
MXPA02010231A (es) * 2001-11-27 2004-12-13 Warner Lambert Co Inhibidores aminotransferasa dependientes de aminoacidos de cadena ramificada y su uso en el tratamiento de las enfermedades neurodegenerativas.

Also Published As

Publication number Publication date
US20050014841A1 (en) 2005-01-20
AU2002365311A1 (en) 2003-06-10
US20030149110A1 (en) 2003-08-07
MXPA02010231A (es) 2004-12-13
JP2003206273A (ja) 2003-07-22
CA2412466A1 (en) 2003-05-27
EP1314723A1 (en) 2003-05-28
WO2003045902A1 (en) 2003-06-05
US6809119B2 (en) 2004-10-26

Similar Documents

Publication Publication Date Title
BR0204863A (pt) Inibidores da aminotransferase dependente de aminoacidos de cadeia ramificada e a sua utilização no tratamento de doenças neurodegenerativas
NZ276892A (en) Quinoxalinedione derivatives, preparation and use in pharmaceutical compositions thereof
ES2169848T3 (es) Nuevos aminoacidos ciclicos coronados como agentes farmaceuticos.
BR9707366A (pt) Novos aminoácidos ciclicos como agentes farmacéuticos
BR9708200A (pt) Aminoácidos cíclicos substituídos como agentes farmacéuticos
ATE508738T1 (de) System zur beabstandeten abgabe von arzneimitteln
BRPI0519087B8 (pt) instrumento para inserção de um implante no canal de schlemm do olho
MX2007005306A (es) Formas de dosis oral de liberacion sostenida de la prodroga gabapentina.
DK1187832T3 (da) Aminoheterocycler, som er anvendelige som farmaceutiske midler
BR0113974A (pt) Inibidores de aminotransferase dependente de aminoácido de cadeia ramificada e sua utilização no tratamento de doenças neurodegenerativas
WO2006002096A3 (en) Low doses of l-citrulline for treating diseases
BR0206327A (pt) Inibidores de aminotransferase dependente de aminoácido de cadeia ramificada e seu uso no tratamento de doenças neurodegenerativas
WO2007106862A3 (en) The use of statins to stimulate neurogenesis
BR0113201A (pt) processo para tratar distúrbios neurodegenerativos da retina e da cabeça do nervo óptico
BRPI0513647A (pt) derivados de ácidos 1-fenilalcanocarboxìlicos para o tratamento de doenças neurodegenerativas
EP4364812A3 (en) Intranasal administration of ketamine to cluster headache patients
EP1210100A4 (en) METHOD FOR TREATING INJURIES TO THE TRAUMATIZED BRAIN AND BACK MARKS AND OTHER NEUROGEN CONDITIONS WITH NON-STEROID-INFLAMMATORY-RESISTANT MEDICINES AND NATURALLY APPLICABLE CONOTOXINS
EA200702534A1 (ru) Применение бензоильного производного 3-аминокарбазола для лечения расстройства, связанного с продукцией простагландина e2(pge2)
DE60008111D1 (de) Verwendung von beta-naphtaquinon derivaten zur herstellung eines arzneimittels mit einem hemmenden effekt auf die glutamatfreisetzung durch das gehirn
PT1242089E (pt) Metodos para tratamento e a prevencao de doencas neurodegenerativas
CL2019002936A1 (es) Uso de ácido 1-(aminometil) ciclohexanoacético para preparar un medicamento útil para el tratamiento y prevención de la enfermedad de alzheimer
Van Damme et al. Novel Inhibitors of Angiogenesis
BR9710467A (pt) M-todo para tratamento e preven-Æo de distÚrbios neurodegenerativos atrav-s de administra-Æo de uma tiazolidinona
BRPI0414956A (pt) composições de um inibidor seletivo da ciclooxigenase-2 administradas sob condições hipotérmicas para o tratamento de distúrbios ou lesões do sistema nervoso central mediados por isquemia
WO2020232120A2 (en) Methods for treating arthritis using spl-108 peptide

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A E 6A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 1980 DE 16/12/2008.